EP0091911A4 - Immunohistochemischer nachweis von antinuklearen antikörpern mit glukoseoxidase. - Google Patents

Immunohistochemischer nachweis von antinuklearen antikörpern mit glukoseoxidase.

Info

Publication number
EP0091911A4
EP0091911A4 EP19820902930 EP82902930A EP0091911A4 EP 0091911 A4 EP0091911 A4 EP 0091911A4 EP 19820902930 EP19820902930 EP 19820902930 EP 82902930 A EP82902930 A EP 82902930A EP 0091911 A4 EP0091911 A4 EP 0091911A4
Authority
EP
European Patent Office
Prior art keywords
antigen source
contacting
source
sheath
support
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19820902930
Other languages
English (en)
French (fr)
Other versions
EP0091911A1 (de
Inventor
Tara Rathlev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ICL SCIENTIFIC
ICL SCIENT
Original Assignee
ICL SCIENTIFIC
ICL SCIENT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ICL SCIENTIFIC, ICL SCIENT filed Critical ICL SCIENTIFIC
Publication of EP0091911A1 publication Critical patent/EP0091911A1/de
Publication of EP0091911A4 publication Critical patent/EP0091911A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/552—Glass or silica

Definitions

  • This invention relates generally to immuno ⁇ enzymatic processes for use in medical diagnoses, and more particularly, to an immunohistochemical process for the detection of antinuclear antibodies in test serum.
  • an increasing amount of research has focused on improving clinical laboratory tests.
  • a primary thrust of this research has been to replace the traditional radiotracer labels with safer and more stable labels.
  • fluorescent markers have found wide acceptance. While fluorescent markers give quick results, they have not proven entirely satis- factory for a number of assays because once placed in a detectable state they have a very limited shelf life, fading after a few days or more. Moreover, fluorescent assays frequently exhibit high background due to auto-
  • horseradish peroxidase has not proven entirely satis ⁇ factory, however, because of a high tendency to produce non-specific background stain, even in spite of attempts to quench the presence of endogenous peroxidase-like activity.
  • Another objectionable feature of the peroxi ⁇ dase label is that it generally requires the use of a highly carcinogenic material, diaminobenzidine, for superior stain development. Although substitutes for this material have been developed, their contrast and intensity are typically not entirely satisfactory.
  • the present invention provides an immunohisto- chemical method which substantially reduces the amount of background stain caused by endogenous materials, while producing a relatively permanent record of the assay. Moreover, the reagents of the present invention are relatively inexpensive to manufacture, are stable for long periods of time even when stored at room tempera ⁇ ture, and have minimal carcinogenic characteristics.
  • an immuno ⁇ enzymatic process for the detection of a component of a test sample comprising steps of: contacting the test sample with an antigen source fixed onto support and stabilized by dehydration; contacting the antigen source with an antibody conjugated with glucose oxidase and reactive with the component; incubating the antigen source with the solution containing glucose and a chro ogenic mixture and; analyzing the antigen source for the presence of color from the incubation.
  • the chromogenic mixtures preferably contain t-nitroblue tetrazolium chloride and m-phenazine metho- sulfate, which permit analysis with a light microscope.
  • the component of the test sample is an antinuclear antibody
  • the antigen source fixed on a glass slide is preferably Hep-2 cells or rat kidney tissue, and the conjugated antibody is goat immunoglobulin reactive with human immunoglobulins.
  • an immunohistoche ical method for detecting antinuclear antibodies in a test serum, substantially in the absence of background stain ⁇ ing comprises steps of: providing a nuclear antigen source fixed onto a slide and dehydrated with acetone at about 4 * C;
  • u ⁇ *- U contacting the nuclear antigen source with the test serum; contacting the nuclear antigen source with goat immunoglobulin conjugated with glucose oxidase and reactive with the .antinuclear antibodies; incubating the nuclear antigen source with a solution containing beta-D-glucose, t-nitroblue tetra- zolium, and 1-methoxyphenazine methosulfate; and analyzing the nuclear antigen source under a light microscope for the presence of a formazan stain.
  • Another aspect of the invention is a method of stabilizing an im unochemical substrate fixed on a solid support, the method comprising the steps of: providing a substrate fixed on the support; contacting the substrate with an organic solvent reagent to substantially dehydrate the substrate; placing the support into a protective sheath; backfilling the sheath with a gas; and sealing the support in the sheath.
  • the support is preferably a glass slide, and the substrate Hep-2 cells or rat kidney tissue.
  • the organic solvent reagent can be composed of acetone, methanol, or mixtures thereof, and the interacting step performed between about 4 and 8° C.
  • the sheath can be composed of a polyester film, and can contain a des- sicant.
  • the preferred gas is nitrogen gas.
  • Exemplary starting materials useful in practicing the present invention are slides fixed with human epethelial cells (Hep-2) or with rat kidney tissue suitable for use in antinuclear antibody assays.
  • Such slides can be purchased commercially from a number of sources, including Antibodies Incorporated, Davis, California, and Behring, La Jolla, California, or, alternatively, can be manufactured according to con- ventional techniques. Generally, these slides should be stored at -20°C. to prevent degradation.
  • the slides are immersed ' for about 10 minutes in a bath containing histological grade acetone, methanol, or a combination of these organic solvents.
  • the bath is maintained at a temperature preferably ranging from about 4 C. to about 8 C.
  • After removing the slides from the bath they are allowed to air dry for about 2 to 3 minutes.
  • the slides are preferably stored at about 5°C. during continued processing.
  • the slides are placed into a protective sheath, preferably made from a poly ⁇ ethylene film, such as MYLAR bags with an aluminum outer layer.
  • a protective sheath preferably made from a poly ⁇ ethylene film, such as MYLAR bags with an aluminum outer layer.
  • a small packet containing a standard dessicant is placed in the bag, and the bag is partially sealed. Nitrogen gas is then introduced through the unsealed portion of the bag until the bag bulges slightly. The bag is then totally sealed to prevent the nitrogen gas from escaping.
  • O PI Goat immunoglobulin conjugated with the glucose oxidase enzyme can be prepared as follows. Glucose oxidase, which is available from a variety of commercial sources, including Sigma, St. Louis, Missouri, and Boehringer Manneheim, Indianapolis, Indiana, is dissolved in distilled water at a concentration of about 12 mg/ml. To this solution is added about 0.2 ml of ,0.1 M sodium periodate. The mixture is stirred for about 20 minutes and then dialyzed, preferably against 1 mM sodium acetate buffer, pH 4.4, for about 16 hours.
  • the glucose oxidase solution is mixed with 1 ml of 0.01 M sodium bicarbonate buffer, pH 9.5, containing about 8 mg of the IgG fraction of goat anti- human im unoglobulins (IgG, IgA, and IgM) .
  • 0.1 mis of. an aqueous solution containing about 4 mg/ml sodium borohydrate water solu ⁇ tion is added.
  • the entire mixture can be chromatographed on a gel filtration column, such as a Sephacryl S-300, available from Pharmacia, Piscataway, New Jersey, and the fractions containing the enzyme-IgG conjugate pooled. This pool can then be titrated. to determine working dilutions.
  • a method for detecting antinuclear antibodies utilizing these reagents is performed as follows.
  • a small amount of test serum, or other test solution, is contacted with the nuclear antigen fixed source on the slide. After about thirty minutes at room temperature, the serum is washed from the slide with phosphate buf ⁇ fered saline (PBS) , and then soaked in a cold PBS solu ⁇ tion for about 10 minutes. The slides are removed from the PBS and excess moisture blotted with absorbent paper.
  • a small amount of the enzy e-IgG conjugate, preferably about 50 ul, is contacted with the antigen source for about 30 minutes at room temperature. The slide is again washed with PBS, soaked for 10 minutes in a cold PBS solution, removed, and excess moisture blotted with absorbent paper.
  • the color reagent may be pre ⁇ pared. It consists of about 2 volumes beta-D-glucose, 15 mg/ml in 0.1 M sodium phosphate buffer, pH 6.9, one volume t-nitroblue tatrazolium (t-NBT) , 2 mg/ml in the same buffer (if necessary, this may be filtered through Whattman No. 1 filter paper just prior to use) , and 1 volume of 1-methoxyphenazine methosulfate (m-PMS), 0.8 mg/ml in the same buffer.
  • t-NBT t-nitroblue tatrazolium
  • m-PMS 1-methoxyphenazine methosulfate
  • the preferred chro o- genic reagents are t-NBT and m-PMS, other materials can also be utilized.
  • the mixture may be prepared about 1 hour before the staining reaction.
  • a small volume, preferably about 100 ul, of the color reagents are contacted wtih the antigen source.
  • the slides are placed in a slide chamber and incubated for about 30 minutes at 55 °C. to permit formation of the formazan stain.
  • the excess color reagent is then washed from the slide with PBS, soaked for about 15 minutes in cold PBS and the excess moisture again removed with the absorbent paper.
  • the slide is then prepared for light microsoope viewing according to standard techniques. Briefly, a glycerol-gelatin mounting medium is placed in a 55°C. incubator for about 5 to 10 minutes for liquefication, and a large drop placed over the antigen source. The antigen source is then covered with a cover slip, taking care to avoid formation of air bubbles. When the slides are examined under a light microscope, the existence of antinuclear antibodies in the test serum will cause slightly enlarged, homo ⁇ geneous dark nuclei to appear, substantially without dark background staining.
  • the present invention provides an ef ⁇ fective, inexpensive, highly visible, and permanent record of an antinuclear antibody assay. Further, the nuclear antigen source fixed onto the slide is extremely stable and does not require storage at low temperatures.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP19820902930 1981-08-31 1982-08-12 Immunohistochemischer nachweis von antinuklearen antikörpern mit glukoseoxidase. Withdrawn EP0091911A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29811281A 1981-08-31 1981-08-31
US298112 1981-08-31

Publications (2)

Publication Number Publication Date
EP0091911A1 EP0091911A1 (de) 1983-10-26
EP0091911A4 true EP0091911A4 (de) 1984-04-06

Family

ID=23149085

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19820902930 Withdrawn EP0091911A4 (de) 1981-08-31 1982-08-12 Immunohistochemischer nachweis von antinuklearen antikörpern mit glukoseoxidase.

Country Status (5)

Country Link
EP (1) EP0091911A4 (de)
CA (1) CA1206092A (de)
ES (2) ES8400773A1 (de)
IT (1) IT1153188B (de)
WO (1) WO1983000877A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4487830A (en) * 1982-05-14 1984-12-11 American Hoechst Corporation Enzyme/immunofluorescent assay for autoantibodies
US4588682A (en) * 1982-12-13 1986-05-13 Integrated Genetics, Inc. Binding nucleic acid to a support
CA1279818C (en) * 1985-03-29 1991-02-05 Cenfold Holdings S.A. Diagnostic testing for micro-organisms
JPS6232363A (ja) * 1985-06-21 1987-02-12 モダン・ダイアグノステイツクス・インコ−ポレ−テツド 抗核抗体の検出方法及び装置
EP0241025A1 (de) * 1986-04-08 1987-10-14 Whittaker Bioproducts, Inc. Verfahren und Substrat für Immunofluoreszenz-Mikroskopie
CA1313818C (en) * 1987-06-03 1993-02-23 Ross Leon Coppel Nuclear antigen la
EP0335293A3 (de) * 1988-03-30 1990-09-12 Hoechst Japan Limited Verfahren zur Herstellung eines analytischen Elements zur Bestimmung von anti-nuklearen Antikörpern
WO2005079814A1 (fr) * 2004-02-20 2005-09-01 Beijing Xinjing Antai Medical And Technology Service Limited Corp. Composition pharmaceutique utilisee pour le traitement de l'avortement spontane recurrent et procede associe
WO2005080980A1 (fr) * 2004-02-20 2005-09-01 Beijing Xinjing Antai Medical And Technology Service Limited Corp. Procede pour diagnostiquer un avortement spontane recurrent immunitaire et procede de traitement et de suivi
US7763418B2 (en) * 2005-07-05 2010-07-27 Cytoskeleton, Inc. Detection of Rho proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008720A1 (de) * 1978-08-19 1980-03-19 BEHRINGWERKE Aktiengesellschaft Diagnostisches Mittel und Verfahren zum Nachweis von antimitochondrialen oder antinukleären Antikörpern

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3146163A (en) * 1962-01-23 1964-08-25 John H Brewer Apparatus for separating certain components from blood
NL154600B (nl) * 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3997657A (en) * 1973-10-15 1976-12-14 American Cyanamid Company Dry slide reagent employed in immunofluorescent test for detection of human antinuclear factor
US3876504A (en) * 1974-06-10 1975-04-08 Early Warning Co Procedure for determination of antigens and antibodies and articles for use therewith
US3979509A (en) * 1974-09-03 1976-09-07 General Electric Company Opaque layer method for detecting biological particles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008720A1 (de) * 1978-08-19 1980-03-19 BEHRINGWERKE Aktiengesellschaft Diagnostisches Mittel und Verfahren zum Nachweis von antimitochondrialen oder antinukleären Antikörpern

Also Published As

Publication number Publication date
EP0091911A1 (de) 1983-10-26
IT8223075A0 (it) 1982-08-31
ES515350A0 (es) 1983-11-01
ES8400773A1 (es) 1983-11-01
WO1983000877A1 (en) 1983-03-17
CA1206092A (en) 1986-06-17
ES8500999A1 (es) 1984-11-01
ES524183A0 (es) 1984-11-01
IT1153188B (it) 1987-01-14

Similar Documents

Publication Publication Date Title
JP3040162B2 (ja) 被検体のアッセイを妨害する物質の存在下における生体液中の被検体の測定法
US4690907A (en) Capillary tube immunoassay
Mason et al. Alkaline phosphatase and peroxidase for double immunoenzymatic labelling of cellular constituents.
US4497899A (en) Immunoassay for Chlamydia trachomatis antigens
EP0094603B1 (de) Enzym/fluoro-immuntest für Autoantikörper
US4469797A (en) Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
US4302534A (en) Chemiluminescent enzyme immunoassay
US4474878A (en) Sandwich EIA for antigen associated with hepatitis
US5312744A (en) Method of immobilizing and preserving an immunologically reactive substance
IE48400B1 (en) Process for immunologic determination tests
CA1210691A (en) Determination of terminal deoxynucleotidyl transferase
US4642285A (en) Sandwich EIA for antigen
IE50457B1 (en) Method for detecting and determining proteinaceous specific binding agents and materials bindable thereto,test composition and test kit therefor
US5187066A (en) Methods for detecting amphiphilic antigens
EP0091911A4 (de) Immunohistochemischer nachweis von antinuklearen antikörpern mit glukoseoxidase.
JPH0116388B2 (de)
US4837170A (en) Monoclonal antibody, measuring method of glucosylated protein by utilizing the monoclonal antibody, and kit therefor
CA1104927A (en) Diagnostic immunochemical test material and procedure
CA1302244C (en) Dry test strips having a red blood cell exclusion layer preventing interference by red blood cells in analyte detection visualization
Lebeau et al. Histochemistry and immunohistochemistry on bone marrow biopsies: a rapid procedure for methyl methacrylate embedding
US5128241A (en) Microcapsule immunoassay and reagents therefor
KAMEYA et al. Enzyme-and immuno-histochemical localization of human placental alkaline phosphatase
JPS61275655A (ja) 腫瘍結合標識ｐ５３を検出するための免疫組織化学分析方法
Aarli Localization and Properties of an Acid‐Solubl'e Muscle Antigen Reacting with Antibodies in Myasthenia Gravis Sera
US4460694A (en) Bovine glycoproteins and use in diagnosing infectious mononucleosis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB LI NL

17P Request for examination filed

Effective date: 19830907

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19850817

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RATHLEV, TARA